-
March 11, 2022 Psychedelic Business Spotlight- March 11This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves...
-
March 10, 2022 My Favorite Psychedelic Stocks: Part 1Our resident Psychedelic Investor details five companies he thinks are in strong position to win...
-
March 10, 2022 Psychedelic Researchers Doubt Microdosing in New York TimesAfter a disappointing microdosing study, Dr. Michiel van Elk says the trend is "just not...
-
March 7, 2022 Is Wall Street the Next Stop for Psychedelics? Investing in the Psychedelic Medicine SectorElemental Advisors Inc. CEO Tim Collins paints a picture of the past, present, and future...
-
March 5, 2022 Is There a Difference Between Tripping on LSD and Psilocybin?A double-blinded, randomized, and placebo-controlled study compares the subjective and autonomic effects of both psychedelics.
-
March 4, 2022 Spotlight in Focus: Opioid Crisis Demands Psychedelic Innovation, YesterdayThis month's "Spotlight in Focus" features candid conversation with an opioid addict, and the director...
-
March 4, 2022 Psychedelic Business Spotlight – March 4This week in psychedelic business news: Field Trip partners with Cerebral; Benzinga forms Psychedelic Advisory...
-
March 3, 2022 Study Finds Psilocybin Anti-Depression Effects Last at Least One YearA year after a Johns Hopkins psilocybin-assisted therapy study, researchers find the number of people...
-
March 2, 2022 The Biggest Reason People in Oregon Want to Use PsilocybinSpoiler alert: It's not because they're depressed.
-
March 1, 2022 Dr. Bronner’s Magic Soaps Offers Free Ketamine-Assisted Therapy to Employees"Considering all our advocacy on this issue, this employee benefit is the next logical step,"...
